• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Wells Fargo faces lawsuit over alleged health plan mismanagement and inflated prescription costs

by July 30, 2024
written by July 30, 2024

American financial services giant Wells Fargo & Co. has been hit with a class action lawsuit accusing the bank of mismanaging its employee health insurance plan, which allegedly forced tens of thousands of US employees to overpay for prescription drugs.

Filed on Tuesday in Minnesota federal court, the lawsuit claims the bank violated the Employee Retirement Income Security Act (ERISA), which mandates that companies manage employee health and retirement plans prudently.

This legal action was brought forward by four former employees and follows a pattern of increasing scrutiny on Wells Fargo.

Just a day before, a US judge ordered the bank to face another lawsuit alleging it defrauded shareholders by pretending to commit to hiring diversity, conducting fake job interviews with non-white and female applicants with no intention of hiring them.

US District Judge Trina Thompson in San Francisco found direct and indirect evidence suggesting the bank intended to defraud shareholders about its hiring practices, overturning a previous dismissal of the lawsuit last August.

Allegations of inflated drug prices

The core of the Minnesota lawsuit revolves around claims that Wells Fargo’s health plan pays inflated prices to pharmacy benefit managers (PBMs).

PBMs negotiate with drugmakers, health insurance plans, and pharmacies to set prescription drug prices and determine which drugs are included on their formularies.

The plaintiffs argue that the health plan has been paying exorbitant prices for medications, far above market rates.

One striking example cited in the lawsuit involves the cancer medication bexarotene.

Wells Fargo’s health plan allegedly paid over $69,000 for a tube of bexarotene, which could be purchased for as little as $3,750 at other pharmacies.

Additionally, the lawsuit claims that the health plan marked up the prices of generic “specialty drugs” used to treat certain conditions by nearly 400%.

The lawsuit proposes a nationwide class of health plan participants and beneficiaries, potentially including tens of thousands of people.

The plaintiffs are seeking unspecified damages and statutory penalties, aiming to hold Wells Fargo accountable for the alleged mismanagement and overpricing.

Nationwide scrutiny of PBMs

This lawsuit against Wells Fargo is part of a broader trend of increased scrutiny on PBMs and their role in the rising costs of prescription drugs in the United States.

PBMs are facing growing criticism from government bodies and advocacy groups who argue that their practices contribute significantly to escalating medication prices.

Earlier this month, the Federal Trade Commission (FTC) voted 4-1 to release an interim staff report containing findings from its two-year investigation of the country’s six largest PBMs.

The agency claimed that vertical integration and market consolidation have allowed a few PBMs to exert significant power over drug prices and consumer costs, as well as unaffiliated pharmacies.

Wells Fargo’s lawsuit is the latest in a series of legal actions against employer-sponsored health plans accused of failing to secure lower drug prices for their participants.

Johnson & Johnson is facing a similar proposed class action lawsuit filed in New Jersey federal court in February.

The plaintiffs in that case allege that the company’s mismanagement of its health plan resulted in millions of dollars in overpayments for drugs.

Johnson & Johnson has moved to dismiss the case, arguing that their plan has actually saved participants money and that the named plaintiff lacks legal standing to sue.

As of now, Wells Fargo has not responded to requests for comment on the lawsuit.

The outcome of this case could have significant implications for how employer-sponsored health plans negotiate drug prices and manage PBM relationships in the future.

The post Wells Fargo faces lawsuit over alleged health plan mismanagement and inflated prescription costs appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Biden top adviser Anita Dunn leaves White House for Super PAC supporting Harris
next post
Nasdaq is testing a key support level, which stocks hold the key?

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Pastor recalls last moments with Charlie Kirk: ‘American martyr’

    September 11, 2025
  • Schumer-linked PAC accuses senator of stock ‘greed,’ but financial disclosure contradicts claim

    September 9, 2025
  • The Euro index has a new opportunity to be bullish

    September 5, 2024
  • US military shoots down Houthi drones as Trump’s strikes against terrorist group continue

    March 17, 2025
  • 6 US governors to open talks with Canadian provincial leaders on tariffs

    May 6, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,509)
  • Investing (634)
  • Stock (941)

Latest Posts

  • FLASHBACK: Arizona Dem Senate candidate called Trump voters ‘dumb’: ‘Worst people in the world’

    September 28, 2024
  • After second meeting with Hegseth, Ernst hints at whether she will or won’t support confirmation

    December 10, 2024
  • Trump’s ‘shock and awe’: Forget first 100 days, new president shows off frenetic pace in first 100 hours

    January 23, 2025

Recent Posts

  • Where do Trump’s legal cases stand after massive election win?

    November 8, 2024
  • China says JD Vance’s comments about ‘peasants’ are ‘words that lack knowledge and respect’

    April 8, 2025
  • ‘Doesn’t matter’ which Democrat faces Trump in November, Mike Johnson says

    July 19, 2024

Editor’s Pick

  • Inside how podcasters moved the voting needle with young men ahead of Trump’s massive win

    November 29, 2024
  • Interview: Trump family’s Bitcoin mining deal is a sign of industry legitimization and an ‘influencer endorsement,’ says GoMining CEO Mark Zalan

    April 13, 2025
  • Trump’s midterm convention is the seismic shift that will reshape America

    September 5, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock